Earnings Releases·Nov 9, 2026, 4:08 PM ET

Zentalis Pharmaceuticals — Third Quarter 2026 Earnings Summary

Total operating expenses decreased to $31.2 million in Q3 2026 from $33.7 million in the prior year period, while net loss widened to $28.8 million ($0.34 per share) from $26.7 million ($0.37 per share) year-over-year.
Cash, cash equivalents, and marketable securities increased to $228.9 million as of September 30, 2026, following an August 2026 equity offering that raised approximately $86.9 million, extending the cash runway into the first half of 2028.
The company expects an integrated topline readout from the DENALI Part 2 study in the first half of 2027 and plans to discuss accelerated approval opportunities with the FDA in 2027.
Clinical progress includes complete enrollment for DENALI Parts 2a and 2b with Part 2c concluding in November 2026, alongside ongoing enrollment for the Phase 3 ASPENOVA trial and the MUIR combination study.